Zhejiang Taimei Medical Technology (2576) H2 2024 earnings summary

Executive summary

• FY2024 revenue fell 3.8% YoY to RMB551.2m, while gross profit rose 25.7% and gross margin expanded 9.6 percentage points to 40.8%.

• Net loss narrowed 39.0% to RMB217.4m; adjusted net loss, excluding share-based payments and listing expenses, declined 81.9% to RMB57.3m.

• Focus shifted to core products, operating efficiency and an AI-enabled integrated platform, alongside a planned expansion of customer solutions and international reach.

Financial highlights

• Revenue was RMB551.2m, down 3.8% YoY; gross profit was RMB224.9m, up 25.7%, and operating loss narrowed to RMB252.5m from RMB396.6m.

• Loss for the year was RMB217.4m versus RMB356.4m in 2023; basic and diluted loss per share improved to RMB0.39 from RMB0.64.

• Cost of sales fell 17.2% to RMB326.2m; selling expenses decreased 41.7% to RMB87.6m and R&D expenses decreased 48.5% to RMB87.1m.

• Administrative expenses rose to RMB321.4m from RMB268.9m, mainly reflecting RMB111.3m higher share-based payments, partly offset by lower staff costs.

• Net finance income declined to RMB35.0m from RMB40.2m, primarily due to lower interest income; net other gains rose to RMB14.0m, including higher FX gains and a RMB4.3m litigation provision.

Outlook and guidance

• Plans include an AI clinical research platform integrating trial design, execution, risk forecasting and analysis; stated aims include reducing R&D costs by 30% and increasing trial efficiency by 50%.

• Product plans include global project operations, risk management, medical writing, knowledge tools, multi-cloud deployment and stronger cloud security and compliance capabilities.

• Direct sales and targeted marketing are to be refined; AI development will incorporate customer requirements and joint AI laboratories with biopharmaceutical companies.

• International plans target digital solutions for global multi-center trials and overseas commercialization, serving Chinese and international pharmaceutical and medical device customers.